Suppr超能文献

术前由淋巴细胞、中性粒细胞和白蛋白组成的新指标(LANR)在可手术乳腺癌中的预后价值:一项回顾性研究。

The prognostic value of preoperative neoindices consisting of lymphocytes, neutrophils and albumin (LANR) in operable breast cancer: a retrospective study.

机构信息

Human Reproductive and Genetic Center, Affiliated Hospital of Jiangnan University, Wuxi, China.

Department of Breast Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China.

出版信息

PeerJ. 2024 May 15;12:e17382. doi: 10.7717/peerj.17382. eCollection 2024.

Abstract

BACKGROUND

Preoperative inflammatory factors and nutritional status are strongly associated with the prognosis of a variety of cancers. We explored the relationship between preoperative lymphocytes, neutrophils and albumin (LANR) and progression-free survival in breast cancer patients.

METHODS

The clinical and follow-up data of 200 breast cancer patients were retrospectively analyzed in this study, and the value of LANR was determined as follows: LANR, lymphocytes × albumin/neutrophils. ROC curves, COX proportional risk regression analysis and subgroup analysis were used to assess the prognostic value of LANR in progression-free survival of breast cancer patients.

RESULTS

The median age of the patients was 55.5 years (range 50-62 years). The median follow-up time was 46 months (range 33-55 months). In progression-free survival, the area under the LANR curve was 0.748 and the HR (95% CI) was 0.035 (0.679-0.817). LANR was associated with age ( = 0.02), positive axillary lymph nodes ( < 0.001), TNM stage ( < 0.001) and human epidermal growth factor receptor 2( = 0.004). The results indicated that preoperative LANR may be a reliable predictor of progression-free survival in patients with operable breast cancer.

CONCLUSION

LANR may be an essential predictor for breast cancer patients and provides a therapeutic basis for clinicians and patients.

摘要

背景

术前炎症因子和营养状况与多种癌症的预后密切相关。我们探讨了乳腺癌患者术前淋巴细胞、中性粒细胞和白蛋白(LANR)与无进展生存期之间的关系。

方法

本研究回顾性分析了 200 例乳腺癌患者的临床和随访资料,LANR 值的确定如下:LANR=淋巴细胞×白蛋白/中性粒细胞。采用 ROC 曲线、COX 比例风险回归分析和亚组分析评估 LANR 在乳腺癌患者无进展生存期中的预后价值。

结果

患者的中位年龄为 55.5 岁(范围 50-62 岁)。中位随访时间为 46 个月(范围 33-55 个月)。在无进展生存方面,LANR 曲线下面积为 0.748,HR(95%CI)为 0.035(0.679-0.817)。LANR 与年龄(=0.02)、腋窝淋巴结阳性(<0.001)、TNM 分期(<0.001)和人表皮生长因子受体 2(=0.004)有关。结果表明,术前 LANR 可能是可手术乳腺癌患者无进展生存期的可靠预测指标。

结论

LANR 可能是乳腺癌患者的重要预测指标,为临床医生和患者提供了治疗依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b67/11102052/f4009e4ede1d/peerj-12-17382-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验